New approaches to management of multiple myeloma

Current Treatment Options in Oncology

Volumn 15, Issue 2, 2014, Pages 157-170

  Genadieva Stavric, Sonja ^a   Cavallo, Federica ^b   Palumbo, Antonio ^b  

^a SS CYRIL AND METHODIUS UNIVERSITY OF SKOPJE   (Macedonia)

^b CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

Author keywords

Bortezomib; Carfilzomib; Elderly; Lenalidomide; Multiple myeloma; Novel agents; Thalidomide; Young

Indexed keywords

ALKYLATING AGENT; BORTEZOMIB; CARFILZOMIB; DEXAMETHASONE; DOXORUBICIN; IXAZOMIB CITRATE; LENALIDOMIDE; MELPHALAN; MONOCLONAL ANTIBODY; PERIFOSINE; POMALIDOMIDE; PREDNISONE; PROTEASOME INHIBITOR; ROMIDESPSIN; THALIDOMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BORON DERIVATIVE; BORONIC ACID DERIVATIVE; DEPSIPEPTIDE; GLYCINE; OLIGOPEPTIDE; PHOSPHORYLCHOLINE; PYRAZINE DERIVATIVE; ROMIDEPSIN;

AGE DISTRIBUTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CELL SURVIVAL; COMBINATION CHEMOTHERAPY; CONSOLIDATION CHEMOTHERAPY; DOSE RESPONSE; DRUG DESIGN; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENTIATION; FRAIL ELDERLY; HUMAN; INDUCTION CHEMOTHERAPY; LOW DRUG DOSE; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOMA CELL; ONSET AGE; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; TREATMENT RESPONSE; ADULT; AGE; AGED; ANALOGS AND DERIVATIVES; CLASSIFICATION; MIDDLE AGED; QUALITY OF LIFE; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BORON COMPOUNDS; BORONIC ACIDS; DEPSIPEPTIDES; FRAIL ELDERLY; GLYCINE; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; OLIGOPEPTIDES; PHOSPHORYLCHOLINE; PROTEASOME INHIBITORS; PYRAZINES; QUALITY OF LIFE; RECURRENCE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84902374121     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-014-0276-6     Document Type: Article

References (70)

1. Howlade N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975 2009 (Vintage 2009 Populations), Bethesda, MD: National Cancer Institute. Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975-2009-pops09/, based on November 2011 SEER data submission, posted to the SEER web site, 2012.
2. •• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046-60. A comprehensive review on multiple myeloma.
3. Greipp PR, San Miguel J, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23:3412-20.
4. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leuk Off J Leuk Soc Am Leuk Res Fund UK. 2009;23:3-9.
5. Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23:2210-21.
6. • Avet-Loiseau H, Durie BGM, Cavo M, et al. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia. 2003;27:711-7. A novel approach to better characterize patients and provide appropriate therapy.
7. Stewart AK, Richardson PG, San-Miguel JF. How I treat multiple myeloma in younger patients. Blood. 2009;114:5436-43.
8. Kyle RA, Rajkumar SV. An overview of the progress in the treatment of multiple myeloma. Expert Rev Hematol. 2014;7:5-7.
9. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008;111:2521-6.
10. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516-20.
11. • Turesson I, Velez R, Kristinsson SY, et al. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:830-4. An important article showing the survival trends in myeloma patients.
12. Van de Velde HJK, Liu X, Chen G, et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica. 2007;92:1399-406. (Pubitemid 350144158)
13. •• Gay F, Larocca A, Wijermans P, et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood. 2011;117:3025-31. An important article showing the impact of achieving a complete response in elderly patients.
14. Galimberti S, Benedetti E, Morabito F, et al. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Leuk Res. 2008;29:961-6.
15. Martinelli G, Terragna C, Zamagni E, et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18:2273-81. (Pubitemid 30350220)
16. •• Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010;376:2075-85. One of the most commonly used induction therapies for young patients with multiple myeloma.
17. Cavo M, Pantani L, Petrucci MT, et al. Bortezomib-thalidomide- dexamethasone is superior to thalido-mide- dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012;120:9-19.
18. Sonneveld P, Schmidt-Wolf IGH, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:2946-55.
19. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116:679-86.
20. Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leuk Off J Leuk Soc Am Leuk Res Fund UK. 2009;23:1337-41.
21. Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012;119:4375-82.
22. Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012;120:1801-9.
23. Barlogie B, Attal M, Crowley J, et al. Long-term fol-low- up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and University of Arkansas for medical sciences. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:1209-14.
24. Ladetto M, Pagliano G, Ferrero S, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patientswith autografted myeloma. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:2077-84.
25. Gay F, Magarotto V, Crippa C, et al. Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. Blood. 2013;122:1376-83.
26. •• Ludwig H, Durie BGM, McCarthy P, et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood. 2012;119:3003-15. A major article describing the impact of maintenance therapy.
27. Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. 2012;119:7-15.
28. Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1782-91.
29. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1770-81.
30. Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006;107:3474-80.
31. Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356:1110-20. (Pubitemid 46425595)
32. Cavallo F, Caravita T, Cavalli M, et al. Maintenance therapy with lenalidomide significantly improved survival of young newly diagnosed multiple myeloma patients. Blood. 2013;122:2089.
33. Gay F, Spencer A, Raimondo FD, et al. A phase III study of ASCT vs cyclophosphamide-lenalidomide-dexamethasone and lenalidomide-prednisone maintenance vs lenalidomide alone in newly diagnosed myeloma patients. Blood. 2013;122:763.
34. Gay F, Palumbo A. Management of older patients with multiple myeloma. Blood Rev. 2011;25:65-73.
35. Palumbo A, Gay F, Falco P, et al. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation- maintenance in untreated multiple myeloma patients. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:800-7.
36. •• Fayers PM, Palumbo A, Hulin C, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011;118:1239-47. An important article showing the efficacy results of the standard of care for elderly patients melphalan-prednisone-thalidomide.
37. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906-17.
38. Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010;116:4745-53.
39. Morgan GJ, Davies FE, Gregory WM, et al. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood. 2011;118:1231-8.
40. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11:29- 37.
41. .•• Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366:1759-69. An important article showing the impact of maintenance with lenalidomide in the elderly.
42. Mateos M-V, Oriol A, Martínez-López J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 2010;11:934-41.
43. .•• Palumbo A, Bringhen S, Rossi D, et al. Bortezomib- melphalan- prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:5101-9. An important article showing the impact of maintenance with bortezomib and thalidomide in the elderly.
44. Palumbo A, Bringhen S, Larocca A, et al. Bortezomib-melphalan- prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated fol-low- up and improved survival. J Clin Oncol. 2014. doi:10.1200/JCO.2013.52.0023
45. .•• Palumbo A, Cerrato C. Diagnosis and therapy of multiple myeloma. Korean J Intern Med. 2013;28:263-73. An important article on the management of elderly patients.
46. Palumbo A, Mateos M-V, Bringhen S, et al. Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients? Blood Rev. 2011;25:181-91.
47. Palumbo A, Mina R. Management of older adults with multiple myeloma. Blood Rev. 2013;27:133-42.
48. Palumbo A, Magarotto V. Novel treatment paradigm for elderly patients with multiple myeloma. Am J Blood Res. 2011;1:190-204.
49. Niesvizky R, Flinn IW, Rifkin R, et al. Efficacy and safety of three bortezomib-based combinations in elderly, newly diagnosed multiple myeloma patients: results from all randomized patients in the community-based, phase 3b UPFRONT study. ASH Annu Meet Abstr. 2011;118:478.
50. Falco P, Cavallo F, Larocca A, et al. Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. Leukemia. 2013;27:695-701.
51. Offidani M, Corvatta L, Morabito F, et al. How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions. Expert Opin Investig Drugs. 2011;20:779-93.
52. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leuk Off J Leuk Soc Am Leuk Res Fund UK. 2012;26:149-57.
53. Lonial S. Relapsed multiple myeloma. Hematol Educ Program Am Soc Hematol Am Soc Hematol Educ Program. 2010;2010:303-9.
54. Mohty B, El-Cheikh J, Yakoub-Agha I, et al. Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and "retreatment" approaches in the era of novel agents. Leukemia. 2012;26:73-85.
55. Lokhorst H, Einsele H, Vesole D, et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:4521-30.
56. Bladé J, Rosiñol L, Cibeira MT, et al. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood. 2010;115:3655-63.
57. Terpos E, Kanellias N, Christoulas D, et al. Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma. OncoTargets Ther. 2013;6:531-8.
58. •• Anderson KC. Therapeutic advances in relapsed or refractory multiple myeloma. J Natl Compr Cancer Netw. 2013;11:676-9. Highly recommended as an article focusing on future drugs in treatment of patients with multiple myeloma.
59. Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014
60. Lacy MQ, Kumar SK, LaPlant BR, et al. Pomalidomide plus low-dose dexamethasone (pom/ dex) in relapsed myeloma: long-term follow-up and factors predicting outcome in 345 patients. ASH Annu Meet Abstr. 2012;120:201.
61. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:5008-14.
62. Leleu X, Attal M, Arnulf B, et al. High response rates to pomalidomide and dexamethasone in patients with refractory myeloma, final analysis of IFM 2009-02. ASH Annu Meet Abstr. 2011;118:812.
63. Miguel JS, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:1055-66.
64. Wang Z, Yang J, Kirk C, et al. Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib. Drug Metab Dispos Biol Fate Chem. 2013;41:230-7.
65. Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007;67:6383-91. (Pubitemid 47037522)
66. Alsina M, Trudel S, Furman RR, et al. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18:4830-40.
67. Niesvizky R, Martin III TG, Bensinger WI, et al. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19:2248-56.
68. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120:2817-25.
69. Siegel D, Martin T, Nooka A, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98:1753-61.
70. Allegra A, Alonci A, Gerace D, et al. New orally active proteasome inhibitors in multiple myeloma. Leuk Res. 2014;38:1-9.